Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Heparanase – Drugs In Development, 2022, outlays comprehensive information on the Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Heparanase is an endoglycosidase which cleaves heparan sulfate (HS) and hence participates in degradation and remodeling of the extracellular matrix (ECM). Heparanase is preferentially expressed in human tumors and its over-expression in tumor cells. The enzyme also releases angiogenic factors from the ECM and thereby induces an angiogenic response. Heparanase exhibits also non-enzymatic activities, independent of its involvement in ECM degradation. Among these, are the enhancement of Akt signaling, stimulation of PI3K%li%and p38-dependent endothelial cell migration, and up regulation of VEGF, all contributing to its potent pro-angiogenic activity. Inhibiting the enzyme is beneficial in treatment of cancer. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 4 and 8 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Ophthalmology, Hematological Disorders and Immunology which include indications Coronavirus Disease 2019 (COVID-19), Melanoma, Pancreatic Cancer, Retinopathy, Blood Coagulation, Breast Cancer, Dengue Fever, Dry (Atrophic) Macular Degeneration, Head And Neck Cancer, Inflammation, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Refractory Multiple Myeloma, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Unspecified Cancer and Wet (Neovascular / Exudative) Macular Degeneration.
Furthermore, this report also reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Heparanase – Drugs In Development, 2022, outlays comprehensive information on the Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Heparanase is an endoglycosidase which cleaves heparan sulfate (HS) and hence participates in degradation and remodeling of the extracellular matrix (ECM). Heparanase is preferentially expressed in human tumors and its over-expression in tumor cells. The enzyme also releases angiogenic factors from the ECM and thereby induces an angiogenic response. Heparanase exhibits also non-enzymatic activities, independent of its involvement in ECM degradation. Among these, are the enhancement of Akt signaling, stimulation of PI3K%li%and p38-dependent endothelial cell migration, and up regulation of VEGF, all contributing to its potent pro-angiogenic activity. Inhibiting the enzyme is beneficial in treatment of cancer. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 4 and 8 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Ophthalmology, Hematological Disorders and Immunology which include indications Coronavirus Disease 2019 (COVID-19), Melanoma, Pancreatic Cancer, Retinopathy, Blood Coagulation, Breast Cancer, Dengue Fever, Dry (Atrophic) Macular Degeneration, Head And Neck Cancer, Inflammation, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Refractory Multiple Myeloma, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Unspecified Cancer and Wet (Neovascular / Exudative) Macular Degeneration.
Furthermore, this report also reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166)
- The report reviews Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics and enlists all their major and minor projects
- The report assesses Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Overview
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Companies Involved in Therapeutics Development
B-Side Pharma Ltd
Beta Therapeutics Pty Ltd
CarboMimetics
HepaRx Ltd
Johnson & Johnson
Leadiant Biosciences Inc
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Zucero Therapeutics Ltd
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Drug Profiles
BT-2180 – Drug Profile
Product Description
Mechanism Of Action
History of Events
CM-30119 – Drug Profile
Product Description
Mechanism Of Action
H-1710 – Drug Profile
Product Description
Mechanism Of Action
History of Events
JVB-001 – Drug Profile
Product Description
Mechanism Of Action
JVB-002 – Drug Profile
Product Description
Mechanism Of Action
JVB-003 – Drug Profile
Product Description
Mechanism Of Action
JVB-14 – Drug Profile
Product Description
Mechanism Of Action
History of Events
necuparanib – Drug Profile
Product Description
Mechanism Of Action
History of Events
pixatimod – Drug Profile
Product Description
Mechanism Of Action
History of Events
Polysaccharides to Inhibit Heparanase for Unspecified Cancer – Drug Profile
Product Description
Mechanism Of Action
roneparstat – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit Heparanase for Oncology – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Heparanase for Inflammatory Diseases and Oncology – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Heparanase for Type 1 and Type 2 Diabetes and Age Related Macular Degeneration – Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic Peptide to Inhibit HPSE and VEGF for Oncology – Drug Profile
Product Description
Mechanism Of Action
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Dormant Products
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Discontinued Products
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Product Development Milestones
Featured News & Press Releases
Aug 04, 2016: Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis
Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO
May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting
Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer
May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting
Dec 01, 2014: Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer
Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer
Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer
Jul 21, 2014: European Patent Office Intention to Grant ‘Sulfated Oligosaccharide Derivatives’ Patent
Jun 05, 2014: Momenta Pharmaceuticals Receives Orphan Drug Designation for Necuparanib (Formerly M402) in Pancreatic Cancer
Oct 29, 2013: PG545 Phase 1 Cancer Trial Update
Jul 09, 2013: PG545 Pre-Clinical Data in Experimental Pancreatic Cancer Models Published in Molecular Cancer Therapeutics
May 13, 2013: Sigma-Tau announces Phase I study with new anti-cancer heparanase inhibitor SST0001
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Overview
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Companies Involved in Therapeutics Development
B-Side Pharma Ltd
Beta Therapeutics Pty Ltd
CarboMimetics
HepaRx Ltd
Johnson & Johnson
Leadiant Biosciences Inc
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Zucero Therapeutics Ltd
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Drug Profiles
BT-2180 – Drug Profile
Product Description
Mechanism Of Action
History of Events
CM-30119 – Drug Profile
Product Description
Mechanism Of Action
H-1710 – Drug Profile
Product Description
Mechanism Of Action
History of Events
JVB-001 – Drug Profile
Product Description
Mechanism Of Action
JVB-002 – Drug Profile
Product Description
Mechanism Of Action
JVB-003 – Drug Profile
Product Description
Mechanism Of Action
JVB-14 – Drug Profile
Product Description
Mechanism Of Action
History of Events
necuparanib – Drug Profile
Product Description
Mechanism Of Action
History of Events
pixatimod – Drug Profile
Product Description
Mechanism Of Action
History of Events
Polysaccharides to Inhibit Heparanase for Unspecified Cancer – Drug Profile
Product Description
Mechanism Of Action
roneparstat – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit Heparanase for Oncology – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Heparanase for Inflammatory Diseases and Oncology – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Heparanase for Type 1 and Type 2 Diabetes and Age Related Macular Degeneration – Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic Peptide to Inhibit HPSE and VEGF for Oncology – Drug Profile
Product Description
Mechanism Of Action
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Dormant Products
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Discontinued Products
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Product Development Milestones
Featured News & Press Releases
Aug 04, 2016: Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis
Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO
May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting
Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer
May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting
Dec 01, 2014: Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer
Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer
Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer
Jul 21, 2014: European Patent Office Intention to Grant ‘Sulfated Oligosaccharide Derivatives’ Patent
Jun 05, 2014: Momenta Pharmaceuticals Receives Orphan Drug Designation for Necuparanib (Formerly M402) in Pancreatic Cancer
Oct 29, 2013: PG545 Phase 1 Cancer Trial Update
Jul 09, 2013: PG545 Pre-Clinical Data in Experimental Pancreatic Cancer Models Published in Molecular Cancer Therapeutics
May 13, 2013: Sigma-Tau announces Phase I study with new anti-cancer heparanase inhibitor SST0001
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by B-Side Pharma Ltd, 2022
Pipeline by Beta Therapeutics Pty Ltd, 2022
Pipeline by CarboMimetics, 2022
Pipeline by HepaRx Ltd, 2022
Pipeline by Johnson & Johnson, 2022
Pipeline by Leadiant Biosciences Inc, 2022
Pipeline by Shenzhen Hepalink Pharmaceutical Group Co Ltd, 2022
Pipeline by Zucero Therapeutics Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by B-Side Pharma Ltd, 2022
Pipeline by Beta Therapeutics Pty Ltd, 2022
Pipeline by CarboMimetics, 2022
Pipeline by HepaRx Ltd, 2022
Pipeline by Johnson & Johnson, 2022
Pipeline by Leadiant Biosciences Inc, 2022
Pipeline by Shenzhen Hepalink Pharmaceutical Group Co Ltd, 2022
Pipeline by Zucero Therapeutics Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
